Finally out our paper on sensitive uncommon (Ex18 & Complex mut) EGFR Mut's. In our analysis,we showed that both groups r sensitive n complex mut achieved longer survival compared with Ex18, W/OUT correlation with the Ex20. #LCSM @EGFRResisters @drgandara https://t.co/VNqfPcFaGH https://t.co/LCiRWjpBG7
#TogetherSeparately Webinar: 2023 IASLC Targeted Therapies RecapWednesday, March 15th, 4-5PM ETSpeakers: Dr. Stephen Liu and Dr. Zofia Piotrowska, moderated by Dr. Isabel Preeshagul Link to learn more and register: https://t.co/q8nil5hyyh #lungcancer @lcrf_org
🫁HCP Roundtable: Overcoming #LungCancer Biomarker Testing Challenges WEBINAR! ➡️ https://t.co/d3JJt9uMNw
Hey #LCSM, I'm looking for a familial research study that follows ILN's in family members. Asking for my 22 yr old daughter - Fall 2020 5mm ggo, 6 mths later stable, a yr later (in August) minimal growth (but real), will scan again in August.
1/2
1/2
There are many gaps associated with #Biomarker Testing in #NSCLC. Striking to see that using commercial and medicare claims data, approximately 64% of potentially eligible pts do not get personalized therapy!
@JCOPO_ASCO
https://t.co/5fMRWTPh9b https://t.co/Sm2SqR1Wrc
@JCOPO_ASCO
https://t.co/5fMRWTPh9b https://t.co/Sm2SqR1Wrc
March Newsletter is out! 🫁🧬Post Osi updates, Targeted Therapy 2023 updates, upcoming events and more here ➡️ https://t.co/GOkgdLF5LI #lungcancer @jillfeldman4 @ivybelkins https://t.co/CMKWkJGYay
